Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study
김상현
ARTHRITIS RESEARCH & THERAPY, 202505
2
Impact of csDMARDs vs. b/tsDMARDs on the Prognosis of Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Multicenter, Retrospective Study
김상현
Diagnostics, 202503
3
Risk factors for loss to follow-up in patients with gout: A Korean prospective cohort study
김상현
PLoS One, 202502
4
Complement factor H-related protein 5 alleviates joint inflammation and osteoclast differentiation by disrupting RANK-JNK signaling in collagen antibody-induced arthritis mouse model
김상현
CYTOKINE, 202412
5
Anti-rheumatic property and physiological safety of KMU-11342 in in vitro and in vivo models
김상현
INFLAMMATION RESEARCH, 202408
6
The complement factor H-related protein-5 (CFHR5) exacerbates pathological bone formation in ankylosing spondylitis
김상현
JOURNAL OF MOLECULAR MEDICINE-JMM, 202404
7
Safety and Effectiveness of SB2 (In？iximab Biosimilar) in Adult Patients with Immune-Mediated In？ammatory Diseases: A Post-Marketing Surveillance in Korea
김상현
ADVANCES IN THERAPY, 202403
8
Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry
김상현
Scientific Reports, 202311
9
Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in Korea
김상현
ADVANCES IN THERAPY, 202303
10
Urate-lowering efficacy and renal safety of febuxostat in patients with hyperuricemia and stage 4-5 chronic kidney disease not yet on dialysis: A meta-analysis of observational studies